Sermorelin and CJC-1295 both stimulate the pituitary to release growth hormone, but differ in structure, duration, and clinical strength. Sermorelin is gentler; CJC-1295 produces a stronger, longer-lasting pulse. Neither is FDA-approved for adult anti-aging use. Evaluation at TelosRX is subject to approval by a licensed provider.
Growth hormone peptides are among the most frequently discussed options in longevity and hormone-optimization protocols. Sermorelin and CJC-1295 share a purpose — supporting your own GH production — but they're not interchangeable. The differences matter.
What Is Sermorelin?
Sermorelin is a synthetic peptide comprising the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). These 29 amino acids represent the biologically active portion of GHRH — the segment that binds to pituitary receptors and triggers GH release.
It was originally FDA-approved under the brand name Geref for diagnostic testing of GH deficiency in children. The manufacturer (EMD Serono) voluntarily discontinued Geref in 2008 for commercial reasons, not due to safety concerns. Today, sermorelin is available through compounding pharmacies and used off-label for adult hormone-optimization protocols, subject to evaluation and a provider-issued prescription.
Key pharmacology: sermorelin has a half-life of approximately 10–20 minutes. It produces short, natural-pattern GH pulses that closely mimic physiological secretion. The pituitary's negative feedback system remains intact, preventing excessive GH production. Most protocols dose it once daily at bedtime.
A 1997 study published in the Journal of Clinical Endocrinology & Metabolism showed sermorelin administration increased GH secretion and IGF-1 levels in older adults with age-related GH decline, with improvements in body composition and sleep quality. See the full Sermorelin research guide for additional context.
What Is CJC-1295?
CJC-1295 is a modified GHRH analog — 30 amino acids with chemical modifications that extend its biological half-life and increase receptor binding potency. It stimulates GH release through the same GHRH receptor as sermorelin, but with greater duration and strength.
Two clinically distinct forms exist:
- CJC-1295 without DAC (Modified GRF 1-29): Half-life of ~30 minutes. Produces stronger GH pulses than sermorelin per dose. Almost always paired with ipamorelin in clinical protocols.
- CJC-1295 with DAC (Drug Affinity Complex): Half-life of 6–8 days. Creates sustained GH elevation with 1–2 injections per week. More convenient but blunts the natural pulsatile feedback pattern more significantly.
A pivotal 2006 study in the Journal of Clinical Endocrinology & Metabolism (Teichman et al.) showed CJC-1295 with DAC increased mean GH levels by 2–10 fold and IGF-1 by 1.5–3 fold. CJC-1295 is not FDA-approved. A provider-issued prescription is required; approval is not guaranteed.
Sermorelin vs CJC-1295: Side-by-Side Comparison
| Feature | Sermorelin | CJC-1295 (no DAC) | CJC-1295 (with DAC) |
|---|---|---|---|
| Structure | First 29 aa of GHRH | Modified GHRH analog (30 aa) | GHRH + albumin-binding complex |
| Half-life | 10–20 minutes | ~30 minutes | 6–8 days |
| GH Release Pattern | Short, natural pulses | Stronger, sustained pulses | Continuous elevation |
| Dosing Frequency | Once daily (bedtime) | 1–3× daily or per protocol | 1–2× weekly |
| GH Effect Strength | Modest, physiological | Moderate, more pronounced | Significant, sustained |
| Feedback Preserved? | Excellent | Good | Fair (may blunt feedback) |
| Best For | Sleep, anti-aging, new users | Body composition, performance | Convenience, sustained GH lift |
| Common Pairing | Ipamorelin, GHRP-6 | Ipamorelin (most common) | Sometimes used alone |
| Side Effect Profile | Very mild | Mild | Slightly higher risk |
| FDA Status | Previously approved (Geref, discontinued 2008); off-label adult use | Not approved | Not approved |
Which to Consider for Specific Goals
Sleep Quality and General Anti-Aging
Sermorelin has an advantage here. Its short half-life and natural pulse pattern complement nocturnal GH secretion. When dosed 30 minutes before bed, it enhances the body's own overnight GH surge. Many people report measurable sleep quality improvements within 2–4 weeks.
Body Composition and Recovery
CJC-1295 without DAC (typically combined with ipamorelin) is usually selected for body composition goals. Research has shown that GH elevation — even modest increases — significantly impacts visceral fat reduction and lean mass preservation (Rudman et al., NEJM, 1990). For stronger results, the CJC-1295 + ipamorelin stack is the clinical standard. See the CJC-1295 and Ipamorelin stack overview.
Long-Term Safety and Extended Use
Sermorelin's preservation of natural pituitary feedback makes it more suitable for extended use — some protocols run 6–12+ months continuously. Both are used off-label and require individualized monitoring with lab work (IGF-1, fasting glucose, metabolic panel) and provider oversight.
Side Effects: Sermorelin vs CJC-1295
Both are generally well-tolerated when dosed appropriately. Common side effects include mild injection site reactions, temporary flushing, occasional headaches, mild water retention, and increased appetite.
CJC-1295 — particularly the DAC form — carries a slightly higher risk of joint stiffness, tingling or numbness in extremities, more pronounced water retention, and blood sugar fluctuations.
If you're also on testosterone replacement therapy, discuss how GH peptide therapy interacts with your TRT protocol with your provider before starting.
Who May Be a Candidate — and Who Should Avoid These Peptides
Sermorelin may fit people who:
- Are new to GH peptide therapy and want a conservative starting point
- Prioritize sleep quality and gentle long-term anti-aging support
- Prefer once-daily bedtime dosing
- Have a history of sensitivity to hormone-modulating therapies
CJC-1295 (without DAC) may fit people who:
- Have specific body composition goals — fat reduction, lean mass preservation
- Have used sermorelin and want stronger GH stimulation
- Are active adults with performance or recovery goals
- Have documented low IGF-1 levels on lab work
Both peptides should generally be avoided by: people with active cancer or significant cancer history, uncontrolled diabetes, active pituitary tumors, pregnancy, and anyone under 18 without specialized endocrine care. A licensed provider reviews contraindications as part of the TelosRX evaluation process.
Frequently Asked Questions
Is CJC-1295 stronger than sermorelin?
Yes, in terms of GH pulse amplitude. CJC-1295 produces a more pronounced GH response per dose due to its modified structure and longer receptor binding duration. Sermorelin is gentler and closer to the body's natural GH release pattern. Neither is FDA-approved for adult anti-aging use; both require a licensed provider's evaluation and prescription.
Can sermorelin and CJC-1295 be used together?
Some protocols combine these peptides or alternate between them. Since both stimulate GH through the GHRH receptor, combining them primarily increases total GH stimulation. More commonly, either is paired with ipamorelin for a dual-mechanism protocol. Combination use requires careful provider oversight.
How long does it take to see results from sermorelin or CJC-1295?
Sleep improvements are often the first sign, appearing within 2–4 weeks. Meaningful body composition changes typically require 8–12 weeks. Anti-aging benefits accumulate over 3–6 months. Individual response varies based on baseline GH levels, lifestyle, dosing, and protocol adherence.
Are sermorelin and CJC-1295 FDA-approved?
Sermorelin was previously FDA-approved (as Geref) for diagnostic use in pediatric GH deficiency. The manufacturer discontinued it in 2008 for commercial reasons; the drug was not withdrawn for safety concerns. CJC-1295 has not received FDA approval. Both are compounded and used off-label in adult peptide therapy protocols, subject to evaluation by a licensed provider.
Does CJC-1295 increase testosterone?
CJC-1295 does not directly increase testosterone. Improved growth hormone levels may indirectly support the hormonal environment — through better sleep, body composition, and metabolic function — which can positively influence testosterone. For direct testosterone support, that's a separate discussion from GH peptide therapy.
How is the TelosRX evaluation process for these peptides?
The TelosRX process is fully asynchronous. You complete a health questionnaire, a licensed provider reviews your case and lab work, and if appropriate, a protocol is issued without a synchronous appointment. Compounded peptides are shipped directly. Approval is subject to evaluation; it is not guaranteed regardless of the protocol requested.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.